Pharmaceutical Executive Digest:
Having trouble viewing this e-mail? Click here.
Pharmaceutical Executive Europe E-News
 
 
 
 
 
 

You can now follow us on Twitter at Twitter.com/pharmexecmag
 
Survey
We asked 40 pharma leaders, The European Generic Medicines Agency has recently claimed that the potential fees to be charged by the European Medicines Agency for pharmacovigilance activities are unjustifiably high. Do you agree?

Yes 67%
No 22%
The wording of the fees is not clear 11%

Talk to us:
jupton@advanstar.com

Advertise with us:
Dtaylor-higgins@advanstar.com
25 September, 2012
In this Issue
Who Tops Pharm Exec's 11th Annual Industry Audit?
Compiled by Bill Trombetta, Pharm Exec's 11th Annual Industry aims to provide a snapshot of how well companies are doing in advancing shareholder value. Who tops this year's list? Read more...
Ten Big Pharma Firms Unite in the Name of Best Practice
Ten biopharmaceutical companies have announced the formation of a nonprofit organization, TransCelerate BioPharma, the mission of which is to accelerate the development of new medicines by identifying and solving common drug development challenges. More...
Russian Women Bearing Brunt of Medication Costs
Russia’s mandatory health insurance (MHI) system theoretically provides free, universal healthcare throughout the country; the reality, however, is somewhat different, according to research from Kantar Health. More...
In the Rush Toward Customer Engagement, Is Technology the Saviour?
The central question of Cegedim Relationship Management's annual conference on trends in the life sciences industry was: if the business of pharma is changing at warp speed, then what new strategies and practices are best poised to help companies maintain a competitive advantage? More...
Also in this issue?
The Payer C Change: From Customers to Competitors
Outsourcing: The Macro View
Potential European Pharmacovigilance Fees Criticized

Product Profiles
Sciformix

Statistical methodologies will help you capture and use drug experience data to generate meaningful inferences from pooled and observational data. This paper focuses on one such premier methodology, meta-analysis. We illustrate the application of the traditional methods of meta-analysis and also the more recent Bayesian approach to meta-analysis in the context of RAA (renin-angiotensin-aldosterone) system blockers/antagonists.
Read more


Case Study

Reducing outsourcing costs and cycle-times
Discover how a biotech saved $600,000 on a Phase II contract, compressed the contracting cycle-time from three months to two weeks, and formed a more constructive and collaborative working relationship with their CRO.
Download the case study today.